1 - 7 of 7

Erum A. Hartung, MD, MTR

Erum A. Hartung

Dr. Hartung's clinical and translational research program focuses on autosomal recessive polycystic kidney disease and other genetic kidney diseases, development of new kidney and liver imaging biomarkers, and neurocognitive outcomes in children with chronic kidney disease.


Ingo Helbig, MD

Ingo Helbig

Dr. Helbig is a pediatric neurologist in the Division of Neurology and a core faculty member of the ENGIN Frontier Program.


Douglas L. Hill, PhD

Douglas L. Hill

Dr. Hill’s research interests include identifying strategies to help parents, children, and healthcare providers cope with stressful situations; coping skills in the context of serious illness; how parents develop new goals when a child’s health is declining; good parent beliefs of parents of seriously ill children; and changes in self-concept for parents caring for a child with a life-threatening illness.


Matthew Hodgson, MA, MS, CHRC, CCRP

Matthew Hodgson

Developing and implementing strategy to lead the operations of the research-related regulatory, compliance, and safety programs across all types of research including human, animal, and laboratory-based research.


Michael D. Hogarty, MD

Michael D. Hogarty

Dr. Hogarty is a pediatric oncologist with 20 years' experience as a physician-scientist with a careerlong focus on neuroblastoma translational biology.


Jing Huang, PhD

Jing Huang

Dr. Huang works on methodology development to understand the dynamics of disease activities and inform health management using multivariate longitudinal health data. She also works on data integration in Clinical Research Networks.


Stephen P. Hunger, MD

Stephen P. Hunger

Dr. Hunger's focuses his research on molecular and genomic approaches to identify and clinically evaluate targeted cancer treatments for children with relapsed or high-risk acute lymphoblastic leukemia (ALL) such as Philadelphia chromosome-like (Ph-Like) ALL. The long-term goal of Dr. Hunger’s research is to develop better therapies, improve cure rates, and minimize treatment toxicities for children with ALL.